GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system,  helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said  Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company

QINGDAO, China, April 23, 2026 /PRNewswire/ — Hisense, a leading brand in global consumer electronics and home appliances, today announced the global launch of its latest premium television lineup, the UR9 Series. More than a product launch, UR9 represents a new interpretation of “Natural and Real Color”—one that is not only more vivid, but more natural, comfortable, and true to life for everyday viewing.

At the heart of UR9 is a breakthrough in how color is created and experienced. By generating color directly at the light source, UR9 delivers richer tones, more accurate details, and a viewing experience that feels closer to how the human eye perceives the real world—reducing visual fatigue while enhancing immersion.

This user-centric experience leap comes from Hisense’s industry-leading RGB MiniLED technology. In March 2026, the Consumer Technology Association (CTA) Video Division Board released the official industry definition for RGB LED TVs. As a CTA member, Hisense is a major force in establishing the global industry standard of what real RGB MiniLED is, and continues to push the boundaries of conventional display technology.

At the forefront of this innovation, the Hisense UR9 Series represents a quantum leap in display engineering. Moving beyond traditional MiniLED, it introduces a full RGB MiniLED backlight system, where each LED integrates independent red, green, and blue diodes—enabling unprecedented control over color, brightness, and contrast. This architecture achieves up to 100% of BT.2020 color gamut, delivering color performance that is not only more expansive, but also more precise and lifelike.

Powering this breakthrough is the all-new Hi-View AI Engine RGB processor. Through real-time coordination of color and brightness at the zone level, the processor ensures every frame is dynamically optimized—bringing greater depth, clarity, and balance to each scene.

Beyond visual excellence, the UR9 is engineered as a complete sensory experience. Its integrated 4.1.2 Multi-Channel Surround Sound system, professionally tuned by Devialet, creates a fully immersive 360-degree soundscape. Featuring up-firing height speakers, dedicated surround channels, and a powerful built-in subwoofer, the system delivers cinematic depth, dynamic range, and spatial realism without the need for external equipment.

To ensure consistently comfortable viewing across environments, UR9 also features region-optimized panels—Anti-Reflection & Glare-Free for Europe, Australia and other regions, and Obsidian Panel for the Americas, minimizing distractions from ambient light while preserving picture integrity. For gaming enthusiasts, a native 180Hz refresh rate on selected models delivers ultra-smooth motion and responsiveness, enhancing next-generation gaming experiences to new heights.

Supporting a comprehensive suite of premium formats—including Dolby Vision IQ, IMAX Enhanced, and Filmmaker Mode—the UR9 is built to meet the evolving demands of both content creators and consumers. Its performance is complemented by a refined Pure Elegance Design, featuring a premium metal stand and a near bezel-less finish that seamlessly integrates into any modern living space.

With the launch of the UR9, Hisense brings its vision of Innovating A Brighter Life into sharper focus. By redefining “Natural and Real Color” through true RGB MiniLED, Hisense is not only advancing display technology—but shaping a viewing experience that is more natural, more immersive, and more human-centric.

About Hisense

Hisense, founded in 1969, is a globally recognized leader in home appliances and consumer electronics with operations in over 160 countries, specializing in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 1 globally in the 100-inch and over TV segment (2023-2025). As The Origin of RGB MiniLED, Hisense continues to lead the next-generation RGB MiniLED innovation. As the official sponsor of the FIFA World Cup 2026TM, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide.

SOURCE Hisense